Abstract

Triple-negative breast cancer (TNBC) is the aggressive breast cancer subtype with a bad prognosis. It has been known to lack effective treatment other than non-specific chemotherapy. Antibody-drug conjugates (ADCs) have changed the breast cancer treatment landscape such as Trophoblast cell surface antigen-2 as a target for ADCs. To evaluate sacituzumab govitecan’s efficacy in treating triple-negative breast cancer, the present review searched PubMed/Medline, Clinical Key, EMBASE, ClinicalTrials.gov, and Scopus. The studies included randomized clinical trials (RCTs). The assessment of efficacy was conducted in terms of complete response (CR), partial response (PR), objective response rate (ORR), and clinical benefit rate (CBR). The risk of bias (ROB) was assessed using the revised version of the Cochrane ROB tool. Six eligible RCTs including 861 female patients with TNBC were assessed. The overall random-effects pooled prevalence of CR from the positive outcomes was 0.04 (95% CI: 0.03-0.05, p < 0.001). The partial response (PR) was 0.29 (95% CI: 0.26-0.32 p < 0.001), ORR was 0.29 (95% CI: 0.22-0.36, p < 0.001), and CBR was 0.36 (95% CI: 0.21-0.51, p < 0.001). The results showed that the treatment significantly improved patient outcomes. These findings might help define the efficacy profile of sacituzumab govitecan comprehensively; showing that sacituzumab govitecan is an effective drug in treating TNBC patients and assists in designing future clinical trials.

Key words: Triple-negative breast cancer, Sacituzumab govitecan, antibody-drug conjugate, effectiveness, systemic review